𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Omega-3 Fatty Acid Supplementation Effects on Weight and Appetite in Patients with Alzheimer's Disease: The Omega-3 Alzheimer's Disease Study

✍ Scribed by Gerd Faxén Irving; Yvonne Freund-Levi; Maria Eriksdotter-Jönhagen; Hans Basun; Kerstin Brismar; Erik Hjorth; Jan Palmblad; Bengt Vessby; Inger Vedin; Lars-Olof Wahlund; Tommy Cederholm

Book ID
109130358
Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
123 KB
Volume
57
Category
Article
ISSN
0002-8614

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Omega-3 supplementation in mild to moder
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
✍ Yvonne Freund-Levi; Hans Basun; Tommy Cederholm; Gerd Faxén-Irving; Anita Garlin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

## Abstract ## Background Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega‐3 fatty acids (__ω__3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An associ

The effects of music therapy on reducing
The effects of music therapy on reducing agitation in patients with Alzheimer's disease, a pre-post study
✍ Maryam Zare; Azizeh Afkham Ebrahimi; Behrooz Birashk 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB 👁 3 views

A Memory Clinic model set up to diagnose and treat Alzheimer's Disease early in the course of the illness delayed time to institutionalisation by a median of 9 months compared to controls. Treatment included pre and post diagnostic counselling, and psychosocial interventions.

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##